Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6377103 | 0.78 | MGLL (0.50) | MAPTRAB9ANPSR1KMT2ALMNA | |
| SCHEMBL6377101 | 0.78 | MGLL (0.50) | MAPTRAB9ANPSR1KMT2ALMNA | |
| SCHEMBL6374455 | 0.78 | MAPT (0.67) | MAPTRAB9ANPSR1KMT2ALMNA | |
| SCHEMBL30601557 | 0.78 | CYP3A4 (0.50) | MAPTRAB9AKMT2ALMNAMAPK1 | |
| SCHEMBL3922933 | 0.78 | CYP3A4 (0.50) | MAPTRAB9AKMT2ALMNAMAPK1 | |
| SCHEMBL27454175 | 0.77 | MAPT (0.57) | MAPTRAB9ANPSR1KMT2ALMNA | |
| SCHEMBL11575471 | 0.77 | KMT2A (0.66) | MAPTRAB9ANPSR1KMT2ALMNA | |
| SCHEMBL24149128 | 0.76 | MAPT (0.65) | MAPTRAB9ANPSR1KMT2ALMNA | |
| SCHEMBL20157414 | 0.76 | NPC1 (0.58) | MAPTRAB9ANPSR1KMT2ALMNA | |
| SCHEMBL20157601 | 0.76 | MAPT (0.64) | MAPTRAB9ANPSR1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159465-A1 | 3-(4-Hydroxy-2-methylphenyl)-1,2-benzisoxazol-6-ol; estrogen receptor modulators; ability to compete with 17 beta -estradiol for both Estrogen Receptor alpha and Estrogen Receptor beta; Estrogen Receptor Selective Agonist Antagonist activity; anticancer, antiinflammatory, anticholesterol | WYETH (US) | 2005-07-21 | — | — | US | disclosed |
| US-6884814-B2 | Phenyl benzisoxazoles as estrogenic agents | WYETH (US) | 2005-04-26 | — | — | US | disclosed |
| US-20030207927-A1 | Phenyl benzisoxazoles as estrogenic agents | WYETH | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207927-A1 | Phenyl benzisoxazoles as estrogenic agents | ESR1, ESR2, GPER1 | MAPT 3937/4885RAB9A 2734/4885NPSR1 446/4885 |
| US-20050159465-A1 | 3-(4-Hydroxy-2-methylphenyl)-1,2-benzisoxazol-6-ol; estrogen receptor modulators; ability to compete with 17 beta -estradiol for both Estrogen Receptor alpha and Estrogen Receptor beta; Estrogen Receptor Selective Agonist Antagonist activity; anticancer, antiinflammatory, anticholesterol | ESR2, ESR1, GPER1 | MAPT 4625/4885RAB9A 4335/4885NPSR1 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.